US appeals court revives Teva lawsuit alleging Lilly breached generic Forteo agreement
A U.S. appeals court has revived a lawsuit filed by Teva Pharmaceuticals against Eli Lilly. The case alleges that Lilly broke an agreement that permitted Teva to sell a generic version of Lilly's osteoporosis drug, Forteo.
The original deal was intended to allow Teva to market a lower‑cost version of Forteo, expanding patient access while providing Lilly with compensation. Teva claims Lilly failed to honor the terms, prompting the legal challenge.
The appeals court overturned a lower‑court ruling that had found the agreement expired. By reinstating the lawsuit, the court has reopened the dispute over the generic marketing rights, leaving the outcome uncertain pending further proceedings.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Pharmalittle: We’re reading about a battle between Lilly and Teva, psychedelic drugs, and more”
read at STAT ↗
comments(0)
5-min edit window · permanent after that